GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

Daewon Pharmaceutical Co 003220.KS · KRW

Health Care · KRX · 🇰🇷 South Korea

Compare

7,770

0.00%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Analyst ratings

8 analysts, 1 Feb 2026. The analysts' own views, not ours.

  • 3Strong buy
  • 4Buy
  • 1Hold
  • 0Sell
  • 0Strong sell

Price targets

Brokers' own targets, 1 Feb 2026. Not our view.

Average target 16,320

Low
16,160
Average
16,320
Median
16,320
High
16,800

Forecasts

Analyst averages for the fiscal years ahead

FY2026FY2027FY2028
Revenue₩630.80bn₩664.10bn₩706.00bn
Revenue, highest₩633.86bn₩673.53bn₩712.83bn
Revenue, lowest₩627.74bn₩651.51bn₩697.45bn
Earnings per share518.50686.00976.00
Earnings per share, highest525.021022.71988.27
Earnings per share, lowest510.33482.58960.63
Analysts231

Earnings against forecasts

Earnings per share by fiscal quarter

Q2 2026Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024
Forecast114.71145.7571.33587.47255.98360.06574.42432.74
Reported187.92-814.00-138.00250.00-55.00313.00-36.00436.00
Difference+63.8%-658.5%-293.5%-57.4%-121.5%-13.1%-106.3%+0.8%

Quality and value scores

Models run by our data supplier, not our view and not investment advice

Model

Quality score

4 / 10

Revenue growth 10.8% a year over 10 years. Return on equity -0.5%.

Model fair value

34,280.23

From earnings 564,828.49, from revenue 831,956.15.

Piotroski score

3 / 9

A nine-point test of financial strength, for 31 Dec 2025.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.